Taysha Gene Therapies Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Provided By GlobeNewswire
Last update: Aug 12, 2025
Commenced site activation for REVEAL pivotal trial in accordance with previously aligned upon key design elements, following receipt of No Objection Letter (NOL) from Health Canada and feedback from the FDA; patient enrollment anticipated to begin in Q4 2025
Read more at globenewswire.com
